Skip to content
Once booming biotech stocks enter bearish territory

Biotech companies are experiencing one of their worst stock runs in years as rising interest rates, scientific setbacks and a slowdown in big pharma takeovers hit the sector.

Biotech stocks began to soar in the spring of 2020 as individual investors and hedge funds flocked to the sector amid intense attention to the race to develop new vaccines and drugs for Covid-19. Rising demand for biotech stocks has helped fuel a historic boom in IPOs and venture capital investments through 2021.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.